Pharma companies directory 2026

    Pharmaceutical Companies in Argentina

    Argentine-owned laboratories still invoice roughly two-thirds of domestic pharmaceutical sales, a share that INDEC’s industry series has held through devaluations, and houses such as Roemmers, Bagó, Elea Phoenix, Raffo and Gador remain the names physicians write first in primary care.

    ANMAT, the national medicines, food and medical-technology administration under the Ministry of Health, issues every registro sanitario and inspects plants; without that number a pack cannot be sold, reimbursed or tendered. Demand is then split among PAMI, which covers retirees and is the single largest institutional buyer, IOMA for Buenos Aires provincial employees, the obras sociales that insure formal workers, prepaid medicine firms in Greater Buenos Aires, and a cash retail trade that has learned to reprice weekly when the peso moves. CILFA speaks for the national industry and CAEME for the innovator affiliates; the two lobbies disagree on data exclusivity and import substitution, yet both live with Law 25.649, which obliges physicians to write the generic name. This directory sets out the plants, payers and trade houses a launch team has to brief before choosing a partner, a price band or a detailing plan in Argentina.

    Updated September 2026 · ANMAT — registros sanitarios de medicamentos and authorised establishment listings as of September 2026 · 20 named accounts

    Request a proposal for ArgentinaBrowse the 20 companies

    ~US$7–11bn

    Argentine pharmaceutical market, 2023–2024 (CILFA / IMARC / embassy briefings; peso figures swing with FX)

    ~67%

    Share of industry billing from nationally produced medicines (INDEC, 2024 quarters)

    ~5m

    PAMI affiliates — the largest single reimbursed medicines population

    US$860m+

    Pharmaceutical exports, 2024 (CILFA), mainly to Latin American neighbours

    Named accounts

    Top pharmaceutical companies in Argentina

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against ANMAT — registros sanitarios de medicamentos and authorised establishment listings (as of 2026-09-04).
    #CompanyHQ
    01ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)Buenos Aires
    02PAMI (INSSJP)Buenos Aires
    03Ministerio de Salud de la NaciónBuenos Aires
    04IOMA (Instituto de Obra Médico Asistencial)La Plata
    05Laboratorios BagóBuenos Aires
    06RoemmersBuenos Aires
    07Elea PhoenixBuenos Aires
    08Laboratorios RaffoBuenos Aires
    09GadorBuenos Aires
    10Laboratorios CassaráBuenos Aires
    11Laboratorios RichmondBuenos Aires
    12Laboratorio PhoenixBuenos Aires
    13BiosidusBuenos Aires
    14Laboratorios MontpellierBuenos Aires
    15Pfizer ArgentinaBuenos Aires
    16Roche ArgentinaBuenos Aires
    17Novartis ArgentinaBuenos Aires
    18Eurofarma ArgentinaBuenos Aires
    19Droguería del SudBuenos Aires
    20FarmacityBuenos Aires

    Primary research

    These are the pharmaceutical companies accounts we study in Argentina

    Need account-level or SKU-level data for a brand in Argentina? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Argentina?

    Primary research, market access & HEOR. Proposals within 48 hours.

    BioNixus research services

    How the market is structured

    ANMAT licences, obras sociales and how packs move after release

    A finished medicine enters commerce only after ANMAT grants a registro and, for locally made product, accepts the plant’s GMP file. Innovator dossiers often travel a longer clock than copies of molecules already on the market, and reliance on FDA or EMA opinions is narrower than in some neighbouring agencies, so affiliates budget an extra year when the active is new to Argentina. Once authorised, the pack is listed with PAMI if the laboratory wants retiree volume: PAMI’s vademecum and its farmácia network decide both the reimbursed price and the substitution rule, and a delisting can erase a chronic-care brand overnight. Obras sociales — union-run funds plus PAMI’s cousin schemes — must cover at least the Plan Médico Obligatorio discount, commonly 40 percent and often 70 percent for chronic therapies, which is why sales forces treat social-security listing as a separate launch from the private prepaid channel. Prepaid firms such as OSDE, Swiss Medical and Galeno negotiate their own formularies and are the usual first home for high-priced specialties. Retail is still fragmented: Droguería del Sud, Rofina and Global Farm feed thousands of independent pharmacies, while Farmacity and a handful of regional chains concentrate OTC facing in the AMBA. Decree 70/2023 and later import-rule changes have shortened some paperwork for finished goods, yet peso scarcity and ANMAT’s inspection calendar remain the binding constraints on when a new SKU actually appears on a shelf in Córdoba or Rosario.

    Local

    Family-controlled Argentine laboratories that still hold the majority of unit sales, run their own plants, and treat PAMI and obra-social listing as the core commercial event.

    • Laboratorios Bagó
    • Roemmers
    • Elea Phoenix
    • Laboratorios Raffo
    • Gador
    • Laboratorios Cassará
    • Laboratorios Richmond
    • Laboratorio Phoenix
    • Biosidus
    • Laboratorios Montpellier

    Multinational

    Innovator affiliates whose value concentrates in prepaid formularies, ministerial vaccine lots and hospital specialties rather than in high-volume social-security generics.

    • Pfizer Argentina
    • Roche Argentina
    • Novartis Argentina

    Regional

    Brazilian and other Latin American groups that open Argentine subsidiaries to fight national houses on branded-generic price and visit frequency.

    • Eurofarma Argentina

    Distributors & importers

    PAMI, IOMA, the ministry, the obras sociales and the national droguerías whose vademecums, credit and depot maps decide whether a registered pack actually moves.

    • ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
    • PAMI (INSSJP)
    • Ministerio de Salud de la Nación
    • IOMA (Instituto de Obra Médico Asistencial)
    • Droguería del Sud
    • Farmacity

    Market structure

    PAMI, obras sociales and the prepaid split

    PAMI’s farmácia network and its vademecum are the first slide in any chronic-care plan: a molecule that is not listed, or that is listed only as an unbranded substitute, will not reach the five million retirees who consume the largest share of cardiovascular, diabetes and CNS packs. The obras sociales add another layer of codes, copayments and delayed payment, and each union fund can prefer a different laboratory for the same INN. Prepaid medicine is smaller in heads but larger in value per script; it is the channel where innovative oncology and immunology brands recover the margin that social security strips out. Mapping those three ledgers separately is more useful than quoting a single national market share.

    Collection risk is part of the product story. PAMI and several obras sociales have stretched payment cycles during inflation spikes, which is why mid-sized houses sometimes walk away from a listed SKU that looks attractive on volume. A launch forecast that ignores days-sales-outstanding at the social-security window will overstate cash and understate the working-capital line that Argentine controllers actually watch.

    CILFA, CAEME and the manufacturing argument

    CILFA’s members argue that national plants already satisfy most unit demand and that import substitution should be defended; CAEME’s members argue that weak data protection and slow ANMAT clocks delay innovative launches. Both statements can be true at once. INDEC’s quarterly billing still shows nationally produced medicines above 65 percent of facturación, while the import bill for APIs and high-value biologics continues to rise. For a foreign brand the practical question is not the lobby talking point but whether ANMAT will accept a foreign GMP file, whether a local plant will toll-manufacture, and whether PAMI will list the result at a price that covers the peso cost of goods.

    What is moving

    What is moving the pharmaceutical market in Argentina

    PAMI vademecum resets after price liberalisation

    Successive PAMI list revisions and reference-price cuts have opened lots that national generics can take from originators, provided the laboratory can finance the receivable and keep the SKU in the farmácia network.

    Export plants as a peso hedge

    Bagó, Roemmers, Elea and Cassará already ship several hundred million dollars a year into neighbouring markets; new ANMAT-inspected capacity is being sold as a regional supply node when domestic real prices compress.

    Prepaid specialty and oncology demand

    OSDE, Swiss Medical and Galeno continue to list high-cost biologics that PAMI will not fund at originator prices, which is why Roche, Pfizer and Novartis still staff medical teams despite a shrinking mass-market share.

    Generic-name prescribing under Law 25.649

    Mandatory INN writing plus pharmacy substitution keeps branded-generic detailing expensive and favours houses that already own the obra-social code and the droguería slot for a given molecule.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Argentina

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Argentina:
    • PAMI vademecum reconstructions by INN: listed brands, reference prices, substitution flags and reported stock-outs across AMBA farmácias.
    • Obra-social versus prepaid formulary comparisons for cardiometabolic and oncology baskets, including copay bands and days-to-pay at union funds.
    • Plant-tour notes at national laboratories covering export share, toll-manufacturing spare capacity and ANMAT inspection findings that delay SKU additions.
    • Independent-pharmacy invoice audits in Buenos Aires, Córdoba and Rosario estimating droguería share and branded-generic penetration after peso spikes.

    Questions

    Frequently Asked Questions

    Which Argentine laboratories still lead unit sales after the latest devaluations?

    Roemmers, Bagó, Elea Phoenix, Raffo, Gador and Cassará recur at the top of audited unit tables, while Pfizer, Roche and Novartis lead in value inside prepaid and hospital specialties. INDEC’s production-versus-import split is a better guide than any single commercial ranking, because social-security prices move with PAMI lists rather than with list-price league tables.

    What does ANMAT require before a new pack can be invoiced?

    A registro sanitario held by an Argentine legal entity, a plant GMP that ANMAT accepts, and labelling in Spanish that matches the approved dossier. Copies of already-marketed molecules usually move faster than first-in-class actives. There is no automatic FDA-to-ANMAT passport of the kind some neighbouring agencies advertise, so affiliates should not copy a Mexican or Chilean timeline.

    Why is PAMI listing treated as a separate launch?

    Retiree volume is large enough to make or break a chronic brand, yet PAMI’s price, substitution and pharmacy-network rules differ from those of OSDE or a union obra social. Winning a prepaid listing does not put the pack into PAMI’s farmácia, and a PAMI delisting does not automatically remove it from prepaid formularies.

    Do foreign companies need a local plant to compete?

    Not for registration, but peso costs, import-licence friction and PAMI preference for nationally produced codes push many affiliates toward toll agreements with Argentine plants. Houses that only import finished goods are more exposed when the central bank rations dollars.

    What evidence does BioNixus collect on Argentine laboratories and payers?

    Interview panels with PAMI auditors, obra-social pharmacy managers and prepaid medical directors in Buenos Aires, Córdoba and Rosario; reconstruction of vademecum entries and reference prices by INN; plant-capacity notes at national laboratories; and purchase-record cuts at independent pharmacies supplied by Droguería del Sud.

    Should the table be read as a sales league?

    No. Names appear because they recur in ANMAT records, PAMI lists, CILFA/CAEME membership and BioNixus interviews. Order is editorial, not a statement of revenue, quality or endorsement.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Argentina. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: ANMAT — registros sanitarios de medicamentos and authorised establishment listings, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Argentina, not size.

    • INDEC Industria farmacéutica en la Argentina quarterly facturación series, 2024; CILFA statements on national-industry share and 2024 exports
    • Indian Embassy Buenos Aires pharmaceutical-sector note, 2024 (ANMAT, PAMI reimbursement, CILFA figures)
    • IMARC and related 2024–2025 peso-to-dollar market-size estimates; Law 25.649 on generic-name prescribing
    • BioNixus Argentina PAMI, obra-social and prepaid-channel fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Argentina?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Argentina?

    Primary research, market access & HEOR. Proposals within 48 hours.